sanofi Archives

Vintage comic-style illustration of three bulls pulling a loaded wagon through sunny farmland, with “EPRX” and “Trio of Bulls” above.

Eupraxia: Three Bullish Analyst Reports Put EP-104GI’s EoE Opportunity in Focus Post Tezspire Results -( $AMGN $APGE $AZN $EPRX $REGN $SNY $TAK )

by John F. Heerdink, Jr. 4 days ago 427Views 0Likes

Wall Street Price targets of $16, $17 and $18 seem to underscore the potential for a long-acting treatment as December clinical data approach Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX) has received a timely vote of confidence from three research firms, with newly…

Biotech professionals collaborate in a modern laboratory with molecular models, digital research displays and blue and green upward arrows symbolizing growth.

Moderna and Novavax Rally: ‘Cancer Vaccine’ Stocks Get a Shot of Investor Confidence -( $IBB $MRK $MRNA $NVAX $SNY $XBI )

by John F. Heerdink, Jr. October 10, 2026 461Views 0Likes

Clinical progress, a proposed U.S. research initiative and vaccine licensing economics strengthen the bull case. Biotechnology investors are finding fresh reasons to look beyond the pandemic trade. Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX) and Merck (NYSE: MRK) rallied on October 9 as…

Promotional graphic for a Tribe Public CEO dinner event featuring Eupraxia Pharmaceuticals (NASDAQ: EPRX), James Helliwell, M.D., and the company’s 52-week EP-104GI clinical update for eosinophilic esophagitis. The image illustrates localized treatment at week zero, durable symptom control through week 52, and a stylized upward EPRX market graphic.

Eupraxia’s One-and-Done EoE Strategy Gains a 52-Week Tailwind -( $EPRX $IBB $REGN $SNY $XBI )

by John F. Heerdink, Jr. September 30, 2026 427Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a potentially important chapter to its eosinophilic esophagitis, or EoE, story: a single administration of its investigational localized therapy, EP-104GI, continued to show clinical-remission signals at 52 weeks in the highest-dose cohorts of the…

Promotional graphic for Tribe Public’s Eupraxia Pharmaceuticals webinar, “Food Shouldn’t Hurt: Why Eupraxia Pharmaceuticals Is Building a More Precise EoE Investment Story,” featuring CEO James Helliwell, MD; EoE inflammation imagery, precision-healing graphics and event details for Friday, August 21, 2026.

Food Shouldn’t Hurt: Why Eupraxia Pharmaceuticals Is Building a More Precise EoE Investment Story -( $EPRX $MRNA $MRK $REGN $SNY $TAK $XBI )

by John F. Heerdink, Jr. August 21, 2026 389Views 0Likes

Tribe Public CEO Presentation & Q&A: Hosted Friday, August 21 Tribe Public hosted its CEO Presentation and Q&A webinar, “Food Shouldn’t Hurt: EOE, Eupraxia, and a Promising New Treatment Approach,” featuring James Helliwell, MD, Chief Executive Officer of Eupraxia Pharmaceuticals Inc. (NASDAQ:…

Eupraxia Pharmaceuticals: A Precision Bet on Making Food Enjoyable Again – Meet CEO At The Tribe Event – Friday, August. 21-( $EPRX $REGN $SNY $TAK )

by John F. Heerdink, Jr. August 17, 2026 300Views 0Likes

For patients with eosinophilic esophagitis, eating can become an exercise in calculated risk rather than a simple pleasure. For Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX), that burden represents both an urgent medical problem and a potentially compelling opportunity to prove that…

The Esophagus Economy: How EP‑104GI Could Reshape EoE Treatment—and Eupraxia’s Valuation -( $EPRX $REGN $SNY )

by John F. Heerdink, Jr. July 20, 2026 240Views 0Likes

Eupraxia Pharmaceuticals, Inc. (NASDAQ: EPRX) is quietly setting up one of the more intriguing biotech inflection points on Wall Street as it marches toward Phase 2b data for EP‑104GI in eosinophilic esophagitis (EoE) this December, with investors increasingly framing the “bar” in…

Eupraxia’s Board Gets A Major Upgrade: Why EPRX Is Suddenly On Grown‑Up Biotech Lists -( $EPRX $IBB $SNY $XBI )

by John F. Heerdink, Jr. July 7, 2026 395Views 0Likes

Eupraxia Pharmaceuticals Inc. (TSX: EPRX, NASDAQ: EPRX) is quietly assembling the kind of boardroom roster that makes Wall Street’s biotech specialists sit up, sharpen their models, and wonder if this “diffusion‑obsessed” Canadian upstart is planning something much bigger than a Phase 2 read‑out. A…

Inside the New Metabolic Gold Rush: How Sanofi’s Tzield, Modular Medical’s Pivot Pump and GLP‑1 Weight‑Loss Drugs Are Reshaping Diabetes Care -( $AZN $GPCR $LLY $MODD $NVO $PFE $SNY )

by John F. Heerdink, Jr. June 26, 2026 505Views 0Likes

Wall Street has a new favorite subplot in the diabetes and obesity saga: a three-act story where Sanofi (SNY) shores up the autoimmune front, Modular Medical (MODD) quietly rewires insulin delivery, and the GLP‑1 heavyweights audition next‑gen obesity drugs on the ADA…

Biologics, Blister Bulls, EOE and Yearly Shots: Why Sanofi and Eupraxia Belong on Every Immunology Watchlist -( $EPRX $REGN $SNY )

by John F. Heerdink, Jr. June 19, 2026 637Views 0Likes

Sanofi’s latest Dupixent win and Eupraxia Pharmaceuticals’ quiet grind in eosinophilic esophagitis (“EoE”) still tell a coherent, investor‑friendly story: the type 2 inflammation boom is alive, and there is room on the highway for both mega‑cap platforms and focused innovators. For investors,…

Eupraxia, Dupixent, and the Race to Redefine EoE Care -( $EPRX $REGN $SNY )

by John F. Heerdink, Jr. May 18, 2026 560Views 0Likes

Eupraxia’s (NASDAQ: EPRX) current analyst chorus post their most recent First Quarter 2026 Financial Results report is now singing from the same hymn book: this is a late-stage GI platform story with cash in the bank, near-term catalysts, and price targets that…

Tag: sanofi

Eupraxia: Three Bullish Analyst Reports Put EP-104GI’s EoE Opportunity in Focus Post Tezspire Results -( $AMGN $APGE $AZN $EPRX $REGN $SNY $TAK )

Moderna and Novavax Rally: ‘Cancer Vaccine’ Stocks Get a Shot of Investor Confidence -( $IBB $MRK $MRNA $NVAX $SNY $XBI )

Eupraxia’s One-and-Done EoE Strategy Gains a 52-Week Tailwind -( $EPRX $IBB $REGN $SNY $XBI )

Food Shouldn’t Hurt: Why Eupraxia Pharmaceuticals Is Building a More Precise EoE Investment Story -( $EPRX $MRNA $MRK $REGN $SNY $TAK $XBI )

Eupraxia Pharmaceuticals: A Precision Bet on Making Food Enjoyable Again – Meet CEO At The Tribe Event – Friday, August. 21-( $EPRX $REGN $SNY $TAK )

The Esophagus Economy: How EP‑104GI Could Reshape EoE Treatment—and Eupraxia’s Valuation -( $EPRX $REGN $SNY )

Eupraxia’s Board Gets A Major Upgrade: Why EPRX Is Suddenly On Grown‑Up Biotech Lists -( $EPRX $IBB $SNY $XBI )

Inside the New Metabolic Gold Rush: How Sanofi’s Tzield, Modular Medical’s Pivot Pump and GLP‑1 Weight‑Loss Drugs Are Reshaping Diabetes Care -( $AZN $GPCR $LLY $MODD $NVO $PFE $SNY )

Biologics, Blister Bulls, EOE and Yearly Shots: Why Sanofi and Eupraxia Belong on Every Immunology Watchlist -( $EPRX $REGN $SNY )

Eupraxia, Dupixent, and the Race to Redefine EoE Care -( $EPRX $REGN $SNY )

Your Guide To Staying Informed In The Markets